^
    1d
    EZHiSWITCH: Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. (clinicaltrials.gov)
    P2, N=900, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    Trial initiation date
    |
    ARID1A (AT-rich interaction domain 1A) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    Ezharmia (valemetostat)
    2d
    SYMPHONY-1: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (clinicaltrials.gov)
    P3, N=555, Active, not recruiting, Epizyme, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Feb 2027
    Enrollment closed • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)
    3d
    PRMT6-mediated EZH2 arginine methylation is critical for breast cancer development. (PubMed, Oncogenesis)
    Combination of PRMT6 inhibitor EPZ020411, and EZH2 inhibitor GSK126 effectively suppresses breast tumour growth in the mouse xenografts...Consistently, PRMT6 mediated EZH2 R509 methylation is also confirmed in PRMT6-knockout mice. Our findings reveal that PRMT6 inhibitors might be promising combination therapy for EZH2-targeting cancer.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    GSK2816126
    5d
    Study of Tazemetostat in Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=6, Terminated, University of Alabama at Birmingham | N=30 --> 6 | Trial completion date: Dec 2029 --> Mar 2026 | Recruiting --> Terminated | Trial primary completion date: Jul 2028 --> Mar 2026; Ipsen, drug company requested all studies using the drug Taxemetostat be terminated due to increased risk of secondary malignancies in subjects.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Tazverik (tazemetostat)
    5d
    Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (clinicaltrials.gov)
    P1/2, N=165, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    doxorubicin hydrochloride • cyclophosphamide • golidocitinib (DZD4205)
    6d
    A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function (clinicaltrials.gov)
    P1, N=18, Terminated, Epizyme, Inc. | Completed --> Terminated; Ipsen decided to discontinue all active tazemetostat clinical trials.
    Trial termination
    |
    Tazverik (tazemetostat)
    6d
    MA-GC-II-022: PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer (clinicaltrials.gov)
    P2, N=78, Recruiting, The First Affiliated Hospital of Zhengzhou University | N=36 --> 78
    Enrollment change
    |
    AiTan (rivoceranib) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554)
    7d
    A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function (clinicaltrials.gov)
    P1, N=18, Completed, Epizyme, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Tazverik (tazemetostat)
    8d
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    9d
    TAZNI: Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Susan Chi, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Tazverik (tazemetostat)
    10d
    Study on the inhibition of thyroid undifferentiated carcinoma metastasis by nanoparticles loaded with EZH2 inhibitor. (PubMed, Transl Cancer Res)
    EZH2 is highly expressed in ATC, and its inhibitors EPZ6438 and GSK343 have anti-cancer potential. Two types of nanoparticles were successfully constructed with good sustained-release, targeting effects, and biosafety. They could improve the therapeutic efficacy and reduce toxic side effects, with GSK343-BSA@CS showing significant effects.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    Tazverik (tazemetostat) • GSK343
    16d
    Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Suspended, University of Utah | Recruiting --> Suspended
    Trial suspension
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Tazverik (tazemetostat)